Tinea infections are fungal infections caused by Tinea rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum. This dermatophyte fungus thrives in humid conditions. Tinea corporis, known as ringworm, is a fungal infection of the arms and legs, or can also occur on any part of the body. Tinea corporis may be acute or chronic and have the tendency to spread to other infected sites.
Acute Tinea pedis causes itchy inflamed red patches and may be pustular and is often caused by fungus such as M. canis. Chronic tinea pedis is most prominent in body folds and is caused by T. rubrum. The clinical features of tinea corpis are round or oval red scaly patches, dry scaling on foot and presence of blisters or pustules on feet and between toes.
The diagnosis of tinea infections is done by dermatologists or general physicians by examining the skin scraping under microscope. Tinea coropis is mostly treated by topical antifungal agents and oral antifungal medicines, such as terbinafine and clotrimazoles, among others.
To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/23134
Dermatologists and podiatrists are increasingly prescribing combination therapy to patients suffering from fungal infections. It has been found that a combination of topical and systemic treatment increases the cure rate when compared to single therapy. Oral anti-fungal drugs are prescribed for a period of three months and later, if topical antifungal agents are unsuccessful.
Oral antifungal medicines include terbinafine and itraconazole. Most of the countries are focusing on prevention of microbial and fungal diseases to reduce their healthcare costs, which in turn is expected to result in high demand for advanced treatment options and diagnostic processes from local governments and third-party payers.
Moreover, increasing research and development activities to develop highly specific antifungal products are also expected to create new growth opportunities for manufacturers operating in the microbial and fungal treatment market.
The global tinea corporis treatment market is apprehended to see impressive growth in the near future due to expansion in use and entry of new products. An encouraging sign can be observed in the market with changing consumer trends.
Access Full TOC of This Report @ https://www.persistencemarketresearch.com/toc/23134
The use of antifungal agents is driven by year on year rise in the susceptible immune compromised patient population, rise in incidence of fungal diseases. Established players are making their mark in many developing economies due to the liberal FDI policies regulated within the pharmaceuticals industry in such countries with increasing consumer inclination towards maintaining aesthetic appearance.
Factors such as adverse side effects associated with antifungal drugs, alternative treatment type plans, lack of awareness about fungal diseases could hamper the growth of the market in the near future
The global market for tinea corporis treatment is segmented on basis of drug class, route of administration, distribution channel and geography:
Segment by Drug Type
- Steroids and Anti-Infective Combinations
Segment by Route of Administration
Segment by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Based on the drug type, the global tinea corporis treatment market is segmented into antifungal drugs and steroids and anti-Infective combinations. Antifungals will dominate the tinea corporis treatment market due to its effectiveness and the only option available for fungal diseases.
For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/23134
More About the Report –
Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.
The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.
Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape
Molecular Diagnostics Market –
Molecular Diagnostics Market Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.
Next-Generation Sequencing Market –
Next Generation Sequencing Market Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.
Ophthalmology devises Market –
Ophthalmology devises Market Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.
Intravenous Iron Drugs Market –
Intravenous (IV) Iron Drugs Market Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.
Syndromes Progressive Ataxia Weakness Disorders Market –
Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.